Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Capital Leases (2018 - 2022)

BioNexus Gene Lab's Capital Leases history spans 5 years, with the latest figure at $13021.0 for Q1 2022.

  • Quarterly results put Capital Leases at $13021.0 for Q1 2022, down 55.02% from a year ago — trailing twelve months through Mar 2022 was $13021.0 (down 55.02% YoY), and the annual figure for FY2021 was $12803.0, down 63.72%.
  • Capital Leases for Q1 2022 was $13021.0 at BioNexus Gene Lab, up from $12803.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $62935.0 in Q4 2018 to a low of $12803.0 in Q4 2021.
  • The 5-year median for Capital Leases is $38169.0 (2020), against an average of $35673.2.
  • The sharpest move saw Capital Leases decreased 19.54% in 2020, then plummeted 63.72% in 2021.
  • Year by year, Capital Leases stood at $62935.0 in 2018, then dropped by 28.36% to $45086.0 in 2019, then fell by 21.72% to $35292.0 in 2020, then plummeted by 63.72% to $12803.0 in 2021, then rose by 1.7% to $13021.0 in 2022.
  • According to Business Quant data, Capital Leases over the past three periods came in at $13021.0, $12803.0, and $18103.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.